1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunotherapy in esophageal cancer
    Book Section

    Greally, M.; Ku, G. Y.
    In Saba, N. F.; El-Rayes, B. F. (Eds.) Esophageal Cancer: Prevention, Diagnosis and Therapy. 2nd ed (2020)

    Fulltext@MSK | Save
  • Chemotherapy induced thrombocytopenia in pediatr solid tumor patients
    Meeting Abstract

    Armstrong, K.; Ortiz, M.; Roberts, S.; Dunkel, I.; Goss, C.; Emily, S.; Soff, G.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Fleming, M. T.; Molina, A. M.; Wolf, S. P.; de Leeuw, R.; Fernandez, C.; Kang, P.; Southwell, T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Al-Ahmadie, H.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Solit, D. B.; Ratna, N.; Regazzi, A. M.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy
    Meeting Abstract

    Lang, J. M.; Kyriakopoulos, C.; Slovin, S. F.; Eickhoff, J. C.; Dehm, S.; Tagawa, S. T.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Comparative circulating tumor DNA (ctD-NA) genomic profiling in 110 patients with advanced renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Gedvilaite, E.; Murray, S. J.; Foster, A.; Motzer, R. J.; Tsui, D.; Voss, M. H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Response to systemic therapy in patients with metastatic fumarate hydratase (FH) deficient renal cell carcinoma (RCC)
    Meeting Abstract

    Gleeson, J. P.; Nikolovski, I.; Kotecha, R.; Ged, Y.; Shapnik, N.; Knezevic, A.; Feldman, D. R.; Lee, C. H.; Voss, M. H.; Chen, Y. B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness
    Meeting Abstract

    Chakraborty, G.; Ghosh, A.; Nandakumar, S.; Armenia, J.; Mazzu, Y. Z.; Atiq, M. O.; Lee, G. S. M.; Mucci, L. A.; Merghoub, T.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study
    Meeting Abstract

    Radford, J.; Bartlett, N.; Straus, D.; Dlugosz-Danecka, M.; Alekseev, S.; Illes, A.; Lech-Maranda, E.; Feldman, T.; Smolewski, P.; Savage, K.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapse/refractory chronic lymphocytic leukaemia
    Meeting Abstract

    Coll Bastus, N.; Bennison, C.; Durno, N.; Sail, K.; Alexiou, D.; Mato, A.; Eyre, T. A.; Follows, G.
    British Journal of Haematology (2020)

    Fulltext@MSK | Save